Noventra Pharma | TirReta Self-Mix 60mg | Compound Peptide Vial
High-Strength Dual Incretin + Multi-Receptor Research Stack (Self-Mix Vial)
TirReta is an investigational hybrid peptide formulation combining Retatrutide and Tirzepatide in a dual-compound research system.
It is referenced in scientific research exploring multi-pathway incretin signalling, receptor interaction dynamics, and complex metabolic peptide synergy within controlled laboratory environments.
Developed as a 60mg self-mix research vial, this formulation is designed for advanced laboratory investigation where compound interaction studies, controlled reconstitution, and multi-receptor profiling are of interest.
🧪 Key Benefits – Noventra Pharma TirReta Self-Mix 60mg Compound Peptide Vial
• Dual-compound research stack combining Retatrutide + Tirzepatide
• Investigated in multi-receptor and incretin pathway research models
• Of interest in metabolic signalling and peptide synergy studies
• 60mg self-mix vial format for laboratory preparation use
• Designed for controlled compound interaction and formulation research
• High-purity investigational formulation from Noventra Pharma
• Manufactured for stability, consistency, and research reliability
• Strictly intended for laboratory research use only
⚖️ DISCLAIMER
This product is intended strictly for laboratory research purposes only. It is not a medicine and has not been evaluated or approved by the South African Health Products Regulatory Authority (SAHPHRA) for human or animal use.
This product is supplied strictly for laboratory research purposes only and is not intended for human consumption.
Products sold on this website are not intended to diagnose, treat, cure, or prevent any disease.
By purchasing, the customer confirms they are qualified to handle and use this product in accordance with applicable laws and regulations.
